Stephens Consulting’s LENZ Therapeutics LENZ Stock Holding History

Stephens Consulting’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$30	–	1209
2025 Q2	$30	Buy	+1	New	+$27	﹤0.01%	1154

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Stephens Consulting's LENZ Position: Q3 2025 in Review

Stephens Consulting sold out of LENZ Therapeutics (LENZ) in Q3 2025, closing a stake of 1 share — an estimated $30 sold.

Stephens Consulting first reported a position in LENZ in Q2 2025 and held it in 1 quarter. The position peaked at $30 in Q2 2025. 166 funds tracked by Wall St. Rank hold LENZ as of Q3 2025.

Stephens Consulting reported no remaining LENZ Therapeutics position as of Q3 2025 after selling out during the quarter.
Stephens Consulting sold 1 LENZ Therapeutics share in Q3 2025, an estimated $30.
Stephens Consulting first reported a position in LENZ Therapeutics in Q2 2025 and held it in 1 quarter.
Stephens Consulting's LENZ Therapeutics position peaked at $30 in Q2 2025.
166 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.